Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
diphtheria-tetanus-acellular pertussis-inactivated poliovirus-haemophilus influenzae type b conjugate vaccine
- Development stage
- Unknown
- Lead developer
- KM Biologics
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The pentavalent DPT-IPV-Hib vaccine, specifically the formulation developed by KM Biologics known as Quinvacta (KMB-202), is a combination vaccine designed for infant immunization. It integrates five components into a single injection: diphtheria toxoid, tetanus toxoid, acellular pertussis (aP) antigens, inactivated poliovirus (IPV), and Haemophilus influenzae type b (Hib) capsular polysaccharide conjugated to a carrier protein. A distinguishing feature of the KM Biologics formulation is the use of Sabin-strain inactivated poliovirus (s-IPV), making it the first 5-in-1 vaccine in Japan to utilize this platform. The vaccine is indicated for the prevention of diphtheria, tetanus, pertussis, poliomyelitis, and invasive diseases caused by Haemophilus influenzae type b. By combining these antigens, the vaccine reduces the total number of injections required in early childhood, potentially improving adherence to vaccination schedules and reducing the burden on healthcare providers and parents.
- Brand names
- Quinvacta
- Other names
- pentavalent DPT-IPV-Hib vaccine5-combined vaccineDPT-sIPV-Hib vaccineDPT-IPV-Hib vaccine
02
Targets
FHA (Filamentous hemagglutinin)FIM2/FIM3 (Fimbriae types 2 and 3)PRNP (Cellular Prion Protein)PRN (Pertactin)Diphtheria toxin
Beyond the preview
Go deeper on diphtheria-tetanus-acellular pertussis-inactivated poliovirus-haemophilus influenzae type b conjugate vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on diphtheria-tetanus-acellular pertussis-inactivated poliovirus-haemophilus influenzae type b conjugate vaccine.